177 related articles for article (PubMed ID: 36562826)
1. BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study.
Friedhoff J; Schneider F; Jurcic C; Endris V; Kirchner M; Sun A; Bolnavu I; Pohl L; Teroerde M; Kippenberger M; Schwab C; Kaczorowski A; Zschäbitz S; Jäger D; Hohenfellner M; Stenzinger A; Duensing A; Duensing S
Cancer Immunol Immunother; 2023 Jun; 72(6):1603-1618. PubMed ID: 36562826
[TBL] [Abstract][Full Text] [Related]
2. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
Braun DA; Hou Y; Bakouny Z; Ficial M; Sant' Angelo M; Forman J; Ross-Macdonald P; Berger AC; Jegede OA; Elagina L; Steinharter J; Sun M; Wind-Rotolo M; Pignon JC; Cherniack AD; Lichtenstein L; Neuberg D; Catalano P; Freeman GJ; Sharpe AH; McDermott DF; Van Allen EM; Signoretti S; Wu CJ; Shukla SA; Choueiri TK
Nat Med; 2020 Jun; 26(6):909-918. PubMed ID: 32472114
[TBL] [Abstract][Full Text] [Related]
3. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
[TBL] [Abstract][Full Text] [Related]
4. Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma.
Takeda K; Bastacky S; Dhir R; Mohebnasab M; Quiroga-Garza GM
Ann Diagn Pathol; 2024 Feb; 68():152223. PubMed ID: 37976977
[TBL] [Abstract][Full Text] [Related]
5. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
6. BAP1-Mutated Clear Cell Renal Cell Carcinoma.
Gallan AJ; Parilla M; Segal J; Ritterhouse L; Antic T
Am J Clin Pathol; 2021 Apr; 155(5):718-728. PubMed ID: 33210135
[TBL] [Abstract][Full Text] [Related]
7. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
[TBL] [Abstract][Full Text] [Related]
8. The expanding role of BAP1 in clear cell renal cell carcinoma.
Kapur P; Rajaram S; Brugarolas J
Hum Pathol; 2023 Mar; 133():22-31. PubMed ID: 35932824
[TBL] [Abstract][Full Text] [Related]
9. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
[TBL] [Abstract][Full Text] [Related]
10. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma.
Chakiryan NH; Hajiran A; Kim Y; Aydin AM; Zemp L; Katende E; Nguyen J; Fan W; Cheng CH; Lopez-Blanco N; Chahoud J; Spiess PE; Fournier M; Dhillon J; Wang L; Moran-Segura C; Mulé J; Du D; Yoder SJ; Berglund A; Teer JK; Manley BJ
Eur Urol Focus; 2022 May; 8(3):784-793. PubMed ID: 33994165
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
Gossage L; Murtaza M; Slatter AF; Lichtenstein CP; Warren A; Haynes B; Marass F; Roberts I; Shanahan SJ; Claas A; Dunham A; May AP; Rosenfeld N; Forshew T; Eisen T
Genes Chromosomes Cancer; 2014 Jan; 53(1):38-51. PubMed ID: 24166983
[TBL] [Abstract][Full Text] [Related]
12. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
[TBL] [Abstract][Full Text] [Related]
13. Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With
Liu Y; Li Y; Xu H; Zhou L; Yang X; Wang C
Int J Surg Pathol; 2023 Dec; 31(8):1485-1494. PubMed ID: 36911986
[TBL] [Abstract][Full Text] [Related]
14. CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma.
Zhou Q; Qi Y; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Xu L; Dai B; Guo J; Zhu Y; Zhang W; Xu J
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32371459
[TBL] [Abstract][Full Text] [Related]
15. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetics of clear-cell renal cell carcinoma.
Brugarolas J
J Clin Oncol; 2014 Jun; 32(18):1968-76. PubMed ID: 24821879
[TBL] [Abstract][Full Text] [Related]
17. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
18. BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials.
Liu K; Huang Y; Xu Y; Wang G; Cai S; Zhang X; Shi T
Cancer Immunol Immunother; 2023 Aug; 72(8):2557-2572. PubMed ID: 37046008
[TBL] [Abstract][Full Text] [Related]
19. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
[TBL] [Abstract][Full Text] [Related]
20. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
